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Abstract The aim of this study was to evaluate the long-
term outcome in 61 patients with medication-overuse
headache (MOH) who 4 years previously had been inclu-
ded in a randomized open-label prospective multicentre
study. Sixty patients still alive after 4 years were invited to
a follow-up investigation. Fifty patients (83%) participated.
Sixteen visited a neurologist, 22 were interviewed through
telephone, 2 gave response by a letter, and 10 were eval-
uated through hospital records. The inﬂuence of baseline
characteristics on outcome 4 years later was evaluated by
non-parametric tests. p values below 0.01 were considered
signiﬁcant. At follow-up, the 50 persons had a mean
reduction of 6.5 headache days/month (p\0.001) and 9.5
acute headache medication days/month (p\0.001) com-
pared to baseline. Headache index/month was reduced
from 449 to 321 (p\0.001). Sixteen persons (32%) were
considered as responders due to a C50% reduction in
headache frequency from baseline, whereas 17 (34%)
persons met the criteria for MOH. None of the baseline
characteristics consistently inﬂuenced all ﬁve outcome
measures. Total Hospital Anxiety and Depression Scale
(HADS) score at baseline was predictors (p\0.005) for
being a responder after 4 years. At 4 years’ follow-up, one-
third of the 50 MOH patients had C50% reduction in
headache frequency from baseline. A low total HADS
score at baseline was associated with the most favorable
outcome.
Keywords Medication-overuse headache  Follow-up 
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Introduction
The prevalence of medication-overuse headache (MOH) is
1–2% in the general population [1–6]. Although MOH is a
common problem worldwide [7], no established consensus
for treatment strategies exists [8]. Scientiﬁc studies on
MOH have accumulated during the past years, but con-
clusions as to the best treatment is scarce due to differences
in deﬁnition of MOH, therapeutic approaches, types of
primary headache, and study design [8]. After treatment,
relapse rates of chronic headache (C15 days/month) com-
bined with medication overuse are typically high. Rela-
tively few follow-up studies have evaluated the long-term
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follow-up data beyond 12 months, most of them were
performed before the introduction of the International
Classiﬁcation of Headache Disorders, 2nd edn (ICHD-II)
[10]. Summarizing data of six follow-up studies, a mean
relapse rate of 26% during the ﬁrst year was found [9],
whereas follow-up studies of longer duration have reported
relapse rates between 20 and 60% [11–17]. The knowledge
about predictors is limited, but in some previous long-term
follow-up studies the prognosis has been reported to be
better, e.g., in women, migraine patients, and in those with
short duration of medication overuse [13–16].
Previously, we performed a randomized open-label
1-year follow-up study of MOH patients diagnosed
according to the revised ICHD-II criteria of MOH [18, 19].
A main ﬁnding was that early introduction of preventive
treatment without a previous detoxiﬁcation program
reduced the suffering of total headache more abruptly than
with just withdrawal [18]. In the last part of the 1-year
follow-up, all included patients were offered the treatment
considered to be optimal for them, preventive treatment
included. However, whether a high focus on prophylactic
treatment during the ﬁrst year could prevent a suggested
high relapse rate was unclear, mainly because very few
prospective long-term studies of MOH patients using the
revised ICHD-II criteria have been performed.
Therefore, the main purpose of the present study was to
evaluate the 4-year follow-up outcome in the group of
MOH-patients that previously were included in the ran-
domized open-label 1-year follow-up. A secondary goal
was to evaluate the inﬂuence of baseline characteristics on
outcome 4 years later.
Methods
The study was approved by the Regional Committee for
Ethics in Medical Research, the Norwegian Data Inspec-
torate, and was registered at ClinicalTrials.gov (number
NCT00918671).
Patients
Sixty patients aged 22–64 years were in the period between
January 2008–May 2010 invited to a 4-years’ follow up.
All had 4 years previously participated in a prospective,
open-labeled multicenter study [18], and at inclusion time
they all fulﬁlled the revised ICHD-II criteria of MOH [19].
The initial study is described in detail previously [18].
Brieﬂy, the majority of patients were included at St. Olav’s
Hospital, where on average 13% of those referred with
suspected MOH were included in the study [18]. Presum-
ably, approximately 500 patients with suspected MOH
were screened during the inclusion period between 2004
and 2006 (Fig. 1). At baseline the patients were randomly
assigned to three different groups; (a) abrupt withdrawal
with start of preventive treatment after 3 months, (b) pre-
ventive treatment from day 1 without abrupt withdrawal,
(c) controls without preventive medication or abrupt with-
drawal. Follow-up visits were scheduled at months 1, 3, 5,
and 12 after inclusion. The controls ﬁnished the study
period after 5 months’ observation, but were then offered
the treatment considered to be optimal for them (withdrawal
or prophylactic treatment) and further follow-up visits.
After the end of the 1-year follow-up, no further regular
visits were offered by the neurologists. The primary care
physician (PCP) might switch medication and treatment
according to their best clinical judgment at any time, or
refer the patient to a neurologist for new consultations.
Study procedure
Individuals living near Trondheim who agreed to partici-
pate were offered a consultation by a neurologist (KH)
including a semi-structured interview. Prior to the visit they
had to complete a headache diary for at least 1 month. In
the headache diary patients recorded daily whether they
Approximately 500 patients referred with 
suspected MOH at baseline
64 underwent 
randomization 
60 invited to 4-
years follow-up
Approximately 436 did not fulfilled the 
inclusion criteria or did not want to 
participate 
1 died 
61 fulfilled the  
inclusion criteria 
50 with follow-up 
data
3 patients had < 15 headache 
days/month according to the diary 
17 Controls 
22 Abrupt withdrawal 
19 Prophylaxis from the start 
 10 without follow-up data 
16 Visited neurologist 
22 Interviewed by telephone 
10 Information through medical 
records 
  2 Response by letter 
Fig. 1 Study ﬂow diagram
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123had headache or not, and if they had headache, its duration
when they were awake, nausea, brand name and number of
doses of acute headache medication, and absence from
work. The headache severity was scored on a 3-point scale
from 1 to 3, explained in the diary as: 1 = mild; does not
inhibit work or other activities, 2 = moderate; inhibits but
does not exclude work or other activities, 3 = severe;
excludes work or other activities.
Individuals living distant to Trondheim agreeing to
participate, were interviewed through telephone by neu-
rologist (KH) using the same semi-structured interview,
concerning headache frequency, headache intensity, head-
ache duration, use of acute medication, use of prophylactic
treatment, and absence from work. Patients interviewed
through telephone or face-to-face were asked to answer
questions in the Hospital Anxiety and Depression Scale
(HADS) and a health-related quality of life-questionnaire
(HRQqL) using the Short Form (SF)-12 [20, 21]. The SF-
12 measures HRQoL in two main domains, a mental health
component score (MCS-12) and a physical health compo-
nent score (PCS-12).
Medical records were checked for individuals who did
not respond to the invitation letter. If they had visited a
neurologist for headache after the 1-year follow-up had
ﬁnished, information about headache frequency and use of
medication during the last consultation was collected.
Outcome measures
The primary outcome measure was the change in number
of headache days/month from the baseline period to the
4-year follow-up. The secondary outcome measures were
change in days with use of acute headache medication/
month, mean headache hours, headache index (HI)/month
(sum of the products of ‘‘headache days/month’’ combined
with ‘‘mean daily hours with headache’’ and ‘‘mean daily
headache severity’’ on days with headache), sick leave
days/month, anxiety and depression measured by HADS,
and SF-12 in two main domains MCS-12 and PCS-12.
At 4-year follow-up, we also estimated number of: (a)
responders deﬁned as those with C50% reduction in
headache days/month compared to baseline and being
without medication overuse, and (b) patients with head-
ache C15 days per month combined with medication
overuse.
Outcome predictors
The inﬂuence of the following baseline characteristics on
outcome was evaluated: sex, age, education level,
employment status, number of years with headache, type of
intervention in the original study (3 groups), original
headache diagnosis, having tried at least two types of
preventive medication prior to randomization, MCS-12,
PCS-12, and HADS (total, depression, and anxiety) score.
We also evaluated whether surgery or onset of medical
conditions like, e.g., depression, or diabetes mellitus type 2
during the follow-up inﬂuenced the outcome.
Statistics
Non-parametric tests were used for comparisons between
groups (Kruskal–Wallis test, Mann–Whitney and Chi-
square test) and within groups (Wilcoxon test) because of
skewed distribution of data. Correlations were evaluated by
Spearman’s rho. More than ten different predictive factors
were evaluated. Multiple comparisons can be associated by
type I error, but the highly conservative Bonferroni-type
corrections can be associated with type-II errors [22].
As a compromise, p values below 0.01 were considered
signiﬁcant.
When appropriate, the inﬂuence of predictors was also
evaluated in multivariate analyses, using logistic regression
(dependent variables: responders or MOH) or linear
regression (dependent variables: headache days/month,
HI/month, or medication days/month). Adjustments were
made for the most important predictors identiﬁed by the
non-parametric tests (i.e., gender, headache diagnosis,
HADS-total, PCS-12, and years with headache). Analyses
were carried out using SPSS version 16.0 for windows
(SPSS Inc., Chicago, IL, USA).
Results
In the original study population of 64 randomized patients,
42 (66%) were included at St. Olav’s Hospital, whereas a
total of 22 (34%) were included from the other hospitals.
Sixty-one patients met the inclusion criteria of MOH
(Fig. 1). The remaining three used triptans [10 days per
month, but had less than 15 headache days/month at
baseline. During the 1-year follow-up one committed sui-
cide, but according to the patient’s GP this was not related
to headache.
Among the 60 participants who met the inclusion criteria
of MOH and were still alive 4 years after randomization,
follow-up data of headache status were available in 50
subjects (83%), whereof 16 visited a neurologist, 22 were
interviewed through telephone, and two gave response by
letter (Fig. 1). In ten patients, headache data were available
in their hospital records. Information about headache was
collected on average 4.0 years (95% CI 3.7–4.2 years) after
randomization. The duration from baseline to end of follow-
up was slightly longer (p = 0.13) for individuals who vis-
ited a neurologist (mean of 4.2 years) compared to those
J Headache Pain (2011) 12:315–322 317
123interviewed through telephone (4.0 years) and to those with
headache data available in medical records (3.5 years)
(Table 1).
Participants versus non-participants
Among the ten persons (17%) without available long-term
follow-up data, the last consultation by a neurologist was
performed 8.3 months (mean) after randomization (SD
3.9). Compared to the 50 patients who participated in the
follow-up, these ten persons experienced somewhat more
prominent reduction in headache days/month (-3.3 vs.
-9.3 days/month, p = 0.07) and headache index/month
(-29 vs. -93, p = 0.36) estimated 5 months after ran-
domization (Table 1). However, none of these differences
were statistically signiﬁcant.
Outcome
At follow-up the group of 50 individuals had a signiﬁcant
reduction in headache days/month, days with use of acute
headache medication/month (Fig. 2), headache index/
month, and days with sick leave compared to baseline,
more prominent at 4-year follow-up than at month 5
(Table 2). Also, physical health component score (PCS-12)
Table 1 Characteristics of the 60 participants related to examination methods at follow-up
Visited
neurologist
Telephone
or letter
Medical
records
No information
available
Statistics
Number (n = 60) 16 24 10 10
Women (%) 44 71 60 70 0.34*
Change in headache days/month at month 5 versus baseline -1.4 -4.6 -3.3 -9.3 0.22

Change in headache index/month at month 5 versus baseline 3.4 -44.4 -42.0 -92.9 0.79

Tried less than two preventive drugs at baseline (%) 63 67 70 90 0.48*
Mean number of years from baseline to end of follow-up (95% CI) 4.2 (3.9–4.5) 4.0 (3.9–4.1) 3.5 (2.5–4.5) 0.8 (0.4–1.1) p\0.001

* Chi-square test
 Between group analyses: Kruskal–Wallis test
Table 2 Efﬁcacy variables (with 95% conﬁdence intervals) at baseline, 5 months and 4 years’ follow-up
Baseline 5 months 4 years
Headache days/month (n = 50) 25.0 (23.2–26.7) 21.6 (18.9–24.4)* 18.4 (15.1–21.8)***
Days with acute headache drugs/month (n = 50) 22.9 (21.0–24.8) 13.3 (10.4–16.3)*** 13.4 (10.3–16.4)***
Headache hours/month (n = 50) 8.1 (6.8–9.4) 8.3 (7.1–9.6) 7.7 (6.2–9.2)
Headache index/month (n = 50) 449 (349–548) 420 (306–534) 320 (224–418)***
Days with sick leave/month (n = 35) 6.3 (1.7–11.0) 2.2 (0.3–4.2)* 0.9 (0.2–1.6)**
Mental health component (MCS-12) (n = 38) 51.2 (44.6–57.7) 57.9 (50.8–64.9)** 62.7 (53.8–71.6)**
Physical health component (PCS-12) (n = 38) 46.7 (40–53.1) 51.0 (43.5–58.5)* 59.8 (51.0–68.6)**
Number of prophylactic drugs tried, mean (n = 50) 1.2 (0.8–1.6) 1.9 (1.4–2.3)*** 2.5 (2.0–3.0)***
*** p B 0.001; ** p B 0.01; * p\0.05
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Fig. 2 Headache days/month and days with acute headache drugs/
month with 95% conﬁdence intervals at baseline, 5, and 50 months
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123and mental component score (MCS)-12 increased signiﬁ-
cantly during the 4-years follow-up for the 38 individuals
with complete data of SF-12 (Table 2).
After 4 years, 20 persons (40%) had headache
\15 days/month, whereof 16 (32% of the total group) had
a C50% reduction in headache frequency compared to
baseline. Thirty individuals (60%) had headache C15 days/
month. Among these, 17 (34% of the total group) still had
MOH, whereas the remaining13 persons did not overuse
acute headache medication. The overused drugs were
triptans (n = 7), simple analgesics (n = 5), or combination
analgesics (n = 5).
At follow-up, 20 individuals (40%) were still using
headachepreventivemedication(7personswithMOHand13
without MOH). The most common drugs were angiotension
IIblockers(n = 6)and/oramitriptyline(n = 6),followedby
b-blockers (n = 4), topiramate (n = 3), and gabapentin
(n = 1). During the time to follow-up, some type of medical
event was recorded in 15 (30%) out of the 50 participants;
onsetofdepression(n = 2),diabetesmellitustype2(n = 2),
myocardialinfarction(n = 1),sometypeofsurgery(n = 8),
alcohol abuse (n = 1), and Graves’disease (n = 1).
Predictors of outcome
The inﬂuence of baseline characteristics on the long-term
outcome evaluated by non-parametric tests is shown in
Table 3. None of them inﬂuenced all ﬁve outcome mea-
sures, and no signiﬁcant predictors were found for head-
ache days/month at 4-years’ follow-up. The strongest
inverse correlation was found between baseline values of
total HADS score and HADS-anxiety score and being a
responder. A signiﬁcant inverse correlation was also found
between PCS-12 and medication days/month after 4 years
(Table 3). No signiﬁcant correlation was found between
type of intervention during the ﬁrst months of follow-up
and outcome at 4-years follow-up.
In a multivariate analysis the correlation between
HADS-anxiety score/total HADS score and being a
responder (adjusted for headache diagnosis), and between
PCS-12 and medication days/month remained statistically
signiﬁcant (adjusted for gender, education level, and years
with headache) (p\0.007).
Discussion
In this 4-year follow-up study, one-third of the MOH
patients still had C50% reduction in headache frequency
from baseline, and two-thirds were without medication
overuse. None of the baseline characteristics consistently
inﬂuenced all outcome measures.
There are, however, some limitations to consider with
the present study. As for all clinical-based studies, one may
Table 3 The inﬂuence of baseline predictors of outcome at 4-years follow-up expressed by p values evaluated by non-parametric tests
Predictors Headache days/month Headache index/month Medication days/month Responders MOH
p value p value p value p value p value
Male 0.019
b 0.035
b 0.051
b 0.14
a 0.18
a
Age 0.85
c (0.03) 0.65
c (0.07) 0.86
c (0.03) 0.22
b 0.56
b
Years with headache 0.03
c (0.31) 0.18
c (0.19) 0.04
c (0.29) 0.23
b 0.045
b
Type of intervention (3 groups) 0.41
b 0.84
b 0.73
b 0.85
a 0.36
a
[2 preventive drugs 0.63
b 0.71
b 0.19
b 0.52
a 0.42
a
MCS-12 0.41
c (0.12) 0.26
c (0.16) 0.67
c (0.06) 0.31
b 0.46
b
PCS-12 0.04
c (0.29) 0.027
c (0.31) 0.007
c (0.38) 0.10
b 0.19
b
HADS-anxiety 0.04
c (0.29) 0.0125
c (0.32) 0.14
c (0.21) 0.004
b 0.15
b
HADS-depression 0.06
c (0.26) 0.0136
c (0.30) 0.057
c (0.27) 0.012
b 0.22
b
HADS-total 0.027
c (0.31) 0.013
c (0.35) 0.056
c (0.27) 0.003
b 0.17
b
Type of drug overused 0.52
b 0.28
b 0.51
b 0.91
a 0.77
a
Headache diagnosis
d 0.02
b 0.006
b 0.12
b 0.027
a 0.82
a
Employed, full-time or part-time 0.08
b 0.06
b 0.25
b 0.14
a 0.18
a
B9 years of education 0.82
b 0.32
b 0.06
b 0.54
a 0.04
a
Surgery during follow-up 0.42
b 0.18
b 0.26
b 0.83
a 0.59
a
a Chi square test
b Kruskal–Wallis test
c Spearman’s rho with correlation coefﬁcient in brackets
d The original headache before they developed MOH at baseline: 18 subjects had pure migraine, 17 tension-type headache without migrainous
features, and 15 mixed headache
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123question to what degree the main results can be general-
ized. In the initial 1-year follow-up study, less than 15% of
patients referred with suspected MOH were included [18].
The majority of these did not fulﬁll the MOH diagnosis,
and only a few of those who fulﬁlled MOH diagnosis
declined to participate. It may also be relevant to point out
that the non-participants in the 4-year follow-up had some-
what greater reduction in headache days/month 5 months
after randomization than those who participated. Hence, our
study population may represent individuals with a particular
highheadacheburden,whichmayatleastpartlyexplainwhy
theburdenofheadachewasstillrelativelyhighafter4 years.
Thus, selective participation could not be ruled out,
and generalization of the results should be done with some
caution, because selective participation could not be ruled
out.
Moreover, many patients did not ﬁll in a headache diary
on a regular basis, and those who visited a neurologist
completed a headache diary only for 1 month. Although all
participants also were asked about use of acute headache
medication and headache frequency during the last
3 months, we cannot rule out that recall bias may have
inﬂuenced our results. Ideally, to verify the diagnosis of
MOH, all participants should have visited a neurologist at
4 years follow-up completing a 3-month headache diary
prior to the visit. However, we had to use other methods of
assessments for those who recently had consulted a neu-
rologist, moved abroad, or lived far from Trondheim.
Using this pragmatic strategy, a high participation rate
(83%) was achieved, but makes the interpretation of the
results more complicated.
Because study design, diagnosis of MOH, and treatment
strategies differ widely between follow-up studies, direct
comparisons of results should be done with caution. In an
Austrian study, one-third of patients were considered to
have a favorable outcome deﬁned as \8 headache days/
month and no drug overuse 5 years after withdrawal [16],
which is similar to the responder rate of 32% at the end of
follow-up in the present study. In contrast, a much higher
responder rate was reported by Andrasik et al. (78%) and
Diener et al. (66%) [11, 23]. However, as already men-
tioned, the present study may to some degree be biased
toward poor outcome due to participation bias, because the
non-participants in the 4-year follow-up had somewhat
more prominent reduction in headache days/month
5 months after randomization. Thus, we cannot rule out the
possibility that the responder rate could have been higher if
all 60 invited persons had participated. Anyway, our
relapse rate of 34% is in fact somewhat lower than the
mean relapse rate of 41% (range 21–60%) reported in
seven previous studies with a follow-up of at least 4 years
(Table 4)[ 11–17]. The prognosis was even better for 109
MOH patients identiﬁed in a population-based survey. In a
1-year follow-up of these patients, 24% still had MOH,
whereas 42% did not experienced chronic headache [24].
In the present study, most of the patients did not have
regular contact with their own PCP or neurologist which at
least to some degree, explain why the burden of headache
was still high after 4 years with a mean of 18.4 headache
days/monthandHI/monthof321.However,comparedtothe
situation5 monthsafterinclusioninthestudy,thenumberof
headache days/month, days with sick leave, and headache
index/month were reduced after 4 years. Accordingly,
the PCS-12 and MCS-12 increased signiﬁcantly during the
4-years’ follow-up for those with complete SF-12 data.
A similar pattern with sustained improvement was reported
byAndrasiketal.ina5-yearfollow-up[15].Possibly,ahigh
focus on the use of preventive treatment during the ﬁrst year
Table 4 Outcome in seven studies with follow-up C 4 years
Publication year
(reference)
Dropout
rate (%)
Headache days/
month baseline
Duration of follow-
up (years, mean)
Headache days/
month Follow-up
Responder
rate
1 (%)
Relapse
rate (%)
Statistical signiﬁcant
predictors
1996 [13]
Ba 30 – 5 – 50
A 40 Number of tablets, duration
of drug abuse
1999 [15]
Ba 61 – 5.9 12.3 – 21 Sex, type of overused drugs
2001 [16]
Bd 12 – 4 – – 60 Number of tablets, duration
of drug abuse
2001 [12]
Bd – – 9.3 – 35
1 33 None
2004 [14]
Ba 22 – 4 – – 45 Headache type, type of
overused drugs
2009 [11]
Bb 45 26.1 5 11.3 78 – None
2010 [17]
Bc 6 – 4 – – 44 Remission at year 1
Mean 29 26.1 5.3 11.8 54 41
A Headache B8 days or less without medication overuse
B MOH diagnosis based on: (a) First version of the International Headache Society (IHS) from 1988 (ICDH-1), (b) criteria proposed by
Silberstein and Lipton in 2000, (c) ICDH-2 or later versions, or (d) other criteria or not clearly stated
320 J Headache Pain (2011) 12:315–322
123of follow-up may have resulted in a sustained improvement.
However,wecannotruleoutthatspontaneousimprovement,
or‘‘regression-to-the-mean’’,atleastinpart,mayexplainthe
favorable course.
In the present study, 60% with MOH at baseline still had
chronic headache (C15 days/month) at 4-year follow-up.
The corresponding long-term prognosis of primary chronic
headaches without medication overuse is largely unknown.
Interestingly, however, among individuals with chronic
TTH or chronic migraine at baseline in 1989, 56% still had
chronic headache in 2001 in a Danish population-based
follow-up study [25].
None of the evaluated baseline predictors had an impact
on all ﬁve outcome measures. It should be emphasized that
we used more conservative statistical methods than most of
the previous long-term follow-up studies, and the chosen
signiﬁcance level (p values below 0.01) could be associated
with a type II error. Although women and individuals with
‘‘pure’’ migraine tended to have more prominent decrease
in headache days/month at 4-years follow-up, a p value
below 0.01 was not achieved. Thus, we could not statisti-
cally conﬁrm a better prognosis in women and migraine
patients which was reported in previous long-term follow-
up studies [14, 15].
In our study, the most favorable outcome was found
for individuals with low total HADS score. In addition, a
signiﬁcant inverse correlation was also found between
PCS-12 and medication days/month after 4 years. Few
other follow-up studies have evaluated the inﬂuence of
HADS score and quality of life at baseline on long-term
outcome. In a 1-year follow-up of MOH patients, self-
reported bodily pain measured by SF-36 was associated
with poor outcome, whereas HADS score did not inﬂuence
signiﬁcantly [26].
Regarding relapse, no signiﬁcant predictors were
found. Number of years with headache did not signiﬁ-
cantly correlate with the diagnosis of MOH at follow-up.
Of relevance, relapses have been associated with duration
of medication overuse in two other long-term follow-up
studies using a p\0.05 as a signiﬁcance level [13, 16].
Unfortunately, information about duration of medication
overuse at inclusion was not available in the present
study. Similarly, the total number of tablets overused was
not measured at baseline, which previously has been
reported to be associated with relapse at follow-up [13,
16]. We did not ﬁnd that relapse was associated with
type of drugs overused as reported by others [14, 15]. It
should be emphasized that the statistical power was
relatively low [18], and our analyses were based on a
lower number of participants (n = 50) than the other
comparable long-term follow-up studies lasting at least
4 years (mean number of participants = 70, range
38–101) [11–16].
With regard to type of intervention no signiﬁcant dif-
ference in headache days/month was found. However,
because all patients had access to the treatment considered
to be optimal for them after the ﬁrst year, no long-term
differences between the groups should be expected.
A total of 17 individuals met the diagnosis of MOH at
4 years’ follow-up. However, it may be questionable whe-
ther all these have MOH in a pathophysiological sense. This
consideration is of relevance for those who performed suc-
cessful withdrawal, but did not experience headache
improvement. Two patients in the withdrawal group (with
the original diagnosis of tension-type headache) did not use
pain killers the ﬁrst 5 months of follow-up, but still had
headache almost every day. However, at 4 years’ follow-up
they fulﬁlled the MOH diagnosis due to overuse of acute
medication, because headache improvement after discon-
tinuationofmedicationoveruseisnolongermandatory[19].
In conclusion, the initial type of intervention did not
inﬂuence the outcome at 4-year follow-up. The long-term
prognosis is relatively favorable as there was a continuing
decline in headache, one-third of the MOH patients having
C50% reduction in headache frequency from baseline, and
two-thirds being without medication overuse. However, the
fact that the total burden of headache was still high after
4 years in this group calls for large and scientiﬁcally well-
designed intervention studies with long-term follow-up to
obtain better treatment regimes for these patients.
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